<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006327</url>
  </required_header>
  <id_info>
    <org_study_id>VAX 003</org_study_id>
    <nct_id>NCT00006327</nct_id>
  </id_info>
  <brief_title>Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand</brief_title>
  <official_title>A Phase III Trial to Determine the Efficacy of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VaxGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the vaccine, AIDSVAX B/E, will protect
      intravenous drug users from becoming infected with HIV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Volunteers are immunized and followed for a minimum of 2 years. Any volunteer that becomes
      infected with HIV-1 is followed every 4 months post infection for up to 36 months. Behavior
      effects associated with study participation are assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1999</start_date>
  <completion_date>August 2000</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>2500</enrollment>
  <condition>HIV Infections</condition>
  <condition>HIV Seronegativity</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MN rgp120/HIV-1 and A244 rgp120/HIV-1</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Volunteers may be eligible for this study if they:

          -  Are 20 to 60 years old.

          -  Are HIV-negative.

          -  Have used intravenous drugs in the previous 12 months.

          -  Are available and commit to 3 years of follow-up.

          -  Have a Thai National ID or its equivalent such as government official ID or state
             enterprise ID.

          -  Are able to understand the study and pass a test showing they understand it, and give
             written informed consent.

        Exclusion Criteria

        Volunteers will not be eligible for this study if they:

          -  Have a serious disease or condition, or history of a serious disease or condition such
             as lymphoma, that would interfere with the study.

          -  Are HIV-positive.

          -  Have ever received an experimental HIV-1 vaccine.

          -  Have had or expect to have any treatments or medications that interfere with the
             immune system (e.g., long-term use of systemic steroids, chemotherapy, or radiation).

          -  Have received a vaccine or immunoglobulin within 2 weeks of receiving the first study
             injection, or other vaccines within 4 weeks of the first study injection.

          -  Have received immunoglobulins for a long time.

          -  Have received non-licensed, research agents within 4 weeks of the first study
             injection.

          -  Expect to miss study visits or plan to move within 36 months.

          -  Are pregnant or breast-feeding or plan to become pregnant during the 36-month study
             period.

          -  Are women who have sex with men and do not plan to use effective birth control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kachit Choopanya</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Kachit Choopanya</name>
      <address>
        <city>Klongsan / Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>June 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2000</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Recombinant Proteins</keyword>
  <keyword>HIV-1</keyword>
  <keyword>AIDS Serodiagnosis</keyword>
  <keyword>Substance Abuse, Intravenous</keyword>
  <keyword>Enzyme-Linked Immunosorbent Assay</keyword>
  <keyword>Blotting, Western</keyword>
  <keyword>HIV Envelope Protein gp120</keyword>
  <keyword>AIDSVAX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

